OncoMatch/Clinical Trials/NCT06793189
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Is NCT06793189 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and Orelabrutinib and Obinutuzumab, Orelabrutinib and Lenalidomide for marginal zone lymphoma(mzl).
Treatment: Obinutuzumab and Orelabrutinib · Obinutuzumab, Orelabrutinib and Lenalidomide · Orelabrutinib · Orelabrutinib — Marginal zone lymphoma (MZL) is a common type of indolent lymphoma that originates from the marginal zone of lymphoid follicles. This study aims to evaluate targeted therapy based on the prognostic risk stratification of MZL-IPI in newly diagnosed MZL cases requiring systemic treatment, and provides a basis for precision treatment of MZL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20-positive)
Histopathologically confirmed CD20-positive marginal zone lymphoma
Disease stage
Required: Stage I, II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic treatment including immunotherapy, chemotherapy or targeted drugs
Previous systemic treatment including immunotherapy, chemotherapy or targeted drugs
Cannot have received: autologous stem-cell transplantation
Previous autologous stem-cell transplantation
Cannot have received: allogeneic tissue/solid organ transplantation
Previous ... allogeneic tissue/solid organ transplantation
Lab requirements
Blood counts
adequate bone marrow function (except those caused by mzl)
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify